Page 18 - Greg Laub News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ian Flinn, MD, leads a roundtable discussion with Loretta Nastoupil, MD, and Amitkumar Mehta, MD

Vinay Prasad, MD, leads a roundtable discussion with Aaron Goodman, MD, and Manni Mohyuddin, MD

Our expert roundtable discusses the long-term efficacy and safety of the IL-23 inhibitor

the recent brought together three expert leaders in their field: moderator Vinay Prasad, MD, is joined by Aaron Goodman, MD, and Al-Ola Abdallah, MD, for a virtual roundtable discussion on the new and potentially practice-changing data from the meeting. In episode one, the physicians debated the follow-up analysis of a trial that questioned the necessity of early versus delayed ASCT, in light of newer therapies we have today. In episode two, Dr. Prasad asked if selinexor, recently approved with support from the phase III BOSTON study, a good drug for the treatment of adults with multiple my...

Following is a transcript of their remarks: Vinay Prasad, MD: I'm back with Aaron Goodman and Al-Ola Abdallah, and we're talking about ASH abstracts. Gentlemen, the myeloma field is excited about CAR-T or cellular therapy and they are going after all sorts of targets. Of course, they start with BCMA [B-cell maturation antigen], but they've expanded from there, and CAR-T therapies are incredibly exciting. Those of us who've used them in lymphoma, who have seen the ability to take a chemo-resistant patient and render them free of disease, folks who have used them in pediatric ALL [acute lymphoc...